This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Ferrous cation is an iron supplement indicated in the treatment of iron deficiency.
- Generic Name
- Ferrous cation
- DrugBank Accession Number
- DB14510
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Ferrous cation (DB14510)
- Weight
- Average: 55.845
Monoisotopic: 55.934942133 - Chemical Formula
- Fe
- Synonyms
- Fe2+
- Ferrous ion
- Iron, ion (Fe2+)
- Iron(2+)
- Iron(2+) ion
- Iron(II) ion
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Iron deficiency •••••••••••• ••••••• •••••••• ••••••• Treatment of Iron deficiency ••• ••• •••••••• •••••••• ••••••• •••••••• •••••••• •••••••• ••••••• Treatment of Iron deficiency ••• ••• •••••• Treatment of Iron deficiency anemia (ida) •••••••••••• •••••••• •••••••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- GW89581OWR
- CAS number
- 15438-31-0
- InChI Key
- CWYNVVGOOAEACU-UHFFFAOYSA-N
- InChI
- InChI=1S/Fe/q+2
- IUPAC Name
- lambda2-iron(2+) ion
- SMILES
- [Fe++]
References
- General References
- AIFA Package Leaflet: TARDYFER (ferrous cation) oral tablets [Link]
- External Links
- PDB Entries
- 1afr / 1aig / 1aij / 1biq / 1cc1 / 1cjx / 1dqk / 1drt / 1dry / 1ds1 … show 1061 more
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Completed Diagnostic Iron Absorption / Post-gastrointestinal bypass surgery / Roux-en-Y Gastric Bypass 1 4 Completed Treatment Iron Deficiency (ID) 1 3 Completed Treatment Chronic Kidney Disease (CKD) / Iron Deficiency Anemia (IDA) 1 3 Completed Treatment Iron Deficiency Anemia (IDA) 4
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet, coated Oral 35 MG Tablet, film coated Oral 50 MG Tablet 65 MG Tablet, film coated Oral 100 MG Capsule Oral 100 mg Granule, effervescent Oral 80 MG Capsule, delayed release Oral 50 MG Tablet, extended release Oral 105 MG Tablet, effervescent Oral 80 MG Capsule, delayed release Oral 100 MG Capsule Oral 50 MG Capsule, extended release Oral 55 MG Tablet, extended release Oral 80 MG Tablet, effervescent Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP -0.77 Chemaxon pKa (Strongest Acidic) 4.58 Chemaxon Physiological Charge 2 Chemaxon Hydrogen Acceptor Count 0 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 0 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 0 m3·mol-1 Chemaxon Polarizability 1.78 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at July 11, 2018 22:43 / Updated at May 14, 2021 01:06